1                         No patient developed human antichimeric antibody.

2 learance accurately predicted development of human antichimeric antibody.

3                         No patient developed human antichimeric antibodies after treatment.

4 nts were evaluated 1-6 mo after infusion for human antichimeric antibody, and none developed a respon

5 however, infusion reactions were common, and human antichimeric antibodies developed in 5 of 14 patie

6                                              Human antichimeric antibody developed in 28% of patients

7 18 levels, soluble IL-2 receptor levels, and human antichimeric antibody (HACA) activity were evaluat

8                                              Human antichimeric antibody (HACA) responses were also c

9                       Six patients developed human antichimeric antibodies (HACAs) at a level > or =1

10 nt (2%) developed an anti-antibody response (human antichimeric antibody/human antimouse antibody).

11                      One patient developed a human antichimeric antibody response predominantly to th

12                                              Human antichimeric antibody response was assessed up to

13                                              Human antichimeric antibody response was evaluated with

14       Only one patient made a very low titer human antichimeric antibody response.

15 he immediate induction of human antimouse or human antichimeric antibody responses.

16 vidence of altered pharmacokinetics or serum human antichimeric antibody titers, for a total of no mo

17                                            A human antichimeric antibody was detected in only one pat